ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection
Sponsor: Vanda Pharmaceuticals
This PHASE3 trial investigates Coronavirus Infection and is currently ongoing. Vanda Pharmaceuticals leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Enrolling By Invitation PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE3
-
May 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE3
Status: Unknown Status → Enrolling By Invitation
-
May 2022 — May 2024 [monthly]
Unknown Status PHASE3
Status: Enrolling By Invitation → Unknown Status
-
Jan 2021 — May 2022 [monthly]
Enrolling By Invitation PHASE3
▶ Show 2 earlier versions
-
May 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Apr 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vanda Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .